You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

COVID-19: Get the latest updates or take a self-assessment.

 

1820 Results
Regimen
Intent: Palliative
Funding:
New Drug Funding Program
    Ipilimumab - Previously Untreated Advanced Unresectable Melanoma
New Drug Funding Program
    Ipilimumab - Previously Treated Advanced Unresectable Melanoma
Mar 2023
Regimen
Cancer Type:
Gastrointestinal, 
Esophagus, 
Gastric / Stomach
Intent: Palliative
Funding:
New Drug Funding Program
    Trastuzumab (Biosimilar) - Advanced Gastric, Gastroesophageal, or Esophageal Cancer
Feb 2023
Regimen
Intent: Palliative
Funding:
ODB - General Benefit
    fulvestrant
Apr 2024
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Palliative
May 2024
Regimen
Intent: Adjuvant
Funding:
Exceptional Access Program
    abemaciclib - For the adjuvant treatment, in combination with endocrine therapy, of adult patients with HR-positive, HER2-negative, node-positive early breast cancer at high risk of disease recurrence based on clinicopathological features and a Ki-67 score of at least 20%.
ODB - General Benefit
    exemestane
Oct 2023
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Lymphoblastic (ALL), 
Leukemia - Acute Myeloid (AML)
Intent: Palliative
Funding:
ODB - General Benefit
    hydroxyurea
Mar 2023
Regimen
Cancer Type:
Lung, 
Mesothelioma (Pleural)
Intent: Palliative
Jun 2021
Regimen
Cancer Type:
Gynecologic, 
Cervix, 
Endometrial, 
Ovary
Intent: Palliative, Adjuvant
Jun 2019
Regimen
Cancer Type:
Lung, 
Mesothelioma (Pleural)
Intent: Palliative
Jun 2021
Regimen
Intent: Adjuvant
Feb 2018
Regimen
Intent: Palliative
Oct 2017
Regimen
Cancer Type:
Gynecologic, 
Endometrial
Intent: Adjuvant
May 2019

Pages